Displaying 1 - 1 of 1
| Active Ingredient | CAPECITABINE |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Metastatic colorectal cancer, locally advanced or metastatic breast cancer after failure of anthracycline-containing chemotherapy. |
| Caution | Diarrhoea (which may be severe), nausea and vomiting, abdominal pain, stomatitis. |
| Dose Range | Initial oral dose 1.25 g/m2 given twice daily . Doses are given for 14 days, followed by a 7-day rest period. |
| Drug Interactions | |
| Pregnancy | Capecitabine may cause fetal harm when administered to pregnant women. Capecitab More ... |
| Breast Feeding | Because of the potential for serious adverse reactions to capecitabine in nursin More ... |